ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$16.71 USD
+0.40 (2.45%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $16.71 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Balance Sheet
Fiscal Year End for ACADIA Pharmaceuticals Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 439 | 417 | 521 | 632 | 697 |
Receivables | 102 | 63 | 65 | 50 | 38 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 36 | 7 | 8 | 10 | 6 |
Other Current Assets | 39 | 21 | 24 | 26 | 19 |
Total Current Assets | 616 | 508 | 618 | 718 | 760 |
Net Property & Equipment | 5 | 6 | 8 | 9 | 3 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 5 | 5 | 6 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 65 | 0 | 0 | 1 | 3 |
Deposits & Other Assets | 6 | 13 | 10 | 7 | 8 |
Total Assets | 749 | 588 | 700 | 783 | 783 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 18 | 13 | 7 | 8 | 7 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 237 | 113 | 89 | 97 | 68 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 254 | 126 | 96 | 106 | 75 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 15 | 9 | 7 | 5 | 3 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 317 | 187 | 159 | 156 | 84 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,863 | 2,771 | 2,695 | 2,613 | 2,403 |
Retained Earnings | -2,431 | -2,370 | -2,154 | -1,986 | -1,704 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 432 | 400 | 541 | 627 | 699 |
Total Liabilities & Shareholder's Equity | 749 | 588 | 700 | 783 | 783 |
Total Common Equity | 432 | 400 | 541 | 627 | 699 |
Shares Outstanding | 164.10 | 161.90 | 160.70 | 158.90 | 154.00 |
Book Value Per Share | 2.63 | 2.47 | 3.37 | 3.95 | 4.54 |
Fiscal Year End for ACADIA Pharmaceuticals Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 439 | 346 | 375 | 403 |
Receivables | NA | 102 | 95 | 84 | 70 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 36 | 21 | 9 | 6 |
Other Current Assets | NA | 39 | 38 | 24 | 24 |
Total Current Assets | NA | 616 | 499 | 493 | 503 |
Net Property & Equipment | NA | 5 | 5 | 5 | 6 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 5 | 5 | 5 | 5 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 65 | 67 | 68 | 70 |
Deposits & Other Assets | NA | 6 | 6 | 19 | 18 |
Total Assets | NA | 749 | 633 | 643 | 655 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 18 | 12 | 19 | 17 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 237 | 197 | 169 | 207 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 254 | 210 | 188 | 224 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 13 | 9 | 5 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 317 | 270 | 247 | 281 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 2,863 | 2,839 | 2,808 | 2,787 |
Retained Earnings | NA | -2,431 | -2,477 | -2,411 | -2,413 |
Other Equity | NA | 0 | 0 | -1 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 432 | 362 | 396 | 374 |
Total Liabilities & Shareholder's Equity | NA | 749 | 633 | 643 | 655 |
Total Common Equity | 0 | 432 | 362 | 396 | 374 |
Shares Outstanding | 164.70 | 164.10 | 164.10 | 163.70 | 162.60 |
Book Value Per Share | 0.00 | 2.63 | 2.21 | 2.42 | 2.30 |